Warning: Declaration of subscribe2_widget::addPluginSubMenu() should be compatible with mijnpress_plugin_framework::addPluginSubMenu($title, $function, $file, $capability = 10, $where = 'plugins.ph...') in /data/32/2/10/97/2499423/user/2737425/htdocs/wordpress1/wp-content/plugins/subscribe2-widget/subscribe2-widget.php on line 18

Warning: Declaration of subscribe2_widget::addPluginContent($links, $file) should be compatible with mijnpress_plugin_framework::addPluginContent($filename, $links, $file, $config_url = NULL) in /data/32/2/10/97/2499423/user/2737425/htdocs/wordpress1/wp-content/plugins/subscribe2-widget/subscribe2-widget.php on line 18
Vivex Biomedical’s Success Story Explored | SEBIO

Vivex Biomedical’s Success Story Explored

Posted by on Sep 9, 2019

Vivex Biomedical’s Success Story Explored

Please join us on Thursday, November 7
, at 3:00 PM at the 21st Annual Southeast BIO Investor & Partnering Forum for a fire-side chat on the emergence, funding, and growth of Vivex Biomedical with “Vivex Biomedical: Tissue-Derived Biologic Therapies.”

VC Panel_v2.jpg


Tom Callaway, venture partner at HealthQuest Capital, will interview the senior leadership that built this Fort Lauderdale-based success. Panelists will include Vivex Founder Tracy S. Anderson who is an Atlanta-based serial entrepreneur, John A. McCallum of private equity firm JAM Capital and Chairman of the Board of Directors, and newly appointed Vivex CEO Peter Wehrly who previously launched InfuseTM  Bone Graft, the world’s first orthobiologic when he led Medtronic Spine and Biologics businesses.

Vivex Biomedical Inc. is a leading regenerative medicine company, dedicated to creating new standards in patient care. Founded in 2013 by Anderson, Vivex strives to create treatment options and solutions that will improve clinical, surgical, and therapeutic patient care through innovation. Vivex acquired the University of Miami Tissue Bank (UMTB) in 2014, a worldwide leader in bone transplantation and tissue-based technology. Together, Vivex and UMTB have distributed more than 2 million tissue allografts to 18 countries worldwide to better serve the needs of patients.

Vivex is also in the pre-launch phase for VIA Disc, a novel product targeted at the treatment of degenerative disc disease (DDD). VIA Disc is a tissue allograft and cellular therapy that is aimed at improving pain and mobility for patients suffering from DDD.

Leave a Reply